Kathryn Jordan Mims

In re Xyrem Antitrust Litigation – Representing Hikma Pharmaceuticals against so-called "reverse payment" allegations relating to Jazz Pharmaceuticals' landmark drug, Xyrem. Trial set for 2025.

In re Gerber Heavy Metals Baby Foods Litigation – Defending Gerber in class action stemming from Congressional report on presence of heavy metals in baby food.

Norton LifeLock / Avast – Represent Avast on US antitrust merger clearance for its $9.2 billion merger with Norton LifeLock.

Nestle v. Motion Industries, Inc. – Represent Nestle USA in action against hardware manufacturer to recover damages for nationwide cookie dough recall.

US v. Grupo Verzatec – Defense of Grupo Verzatec against antitrust challenges to proposed merger.

Pfizer v. Johnson & Johnson – Representing Pfizer in ground-breaking litigation challenging Johnson & Johnson's efforts to deter biosimilar competition in respect of its blockbuster biologic, Remicade.

US v. Anthem – Defense of Anthem, Inc. against US the Department of Justice's lawsuit to block its US$54.2 billion acquisition of Cigna Corporation, the largest merger ever in the health insurance industry. Kathryn was a critical member of the trial team; she took and defended a number of key depositions, was responsible for preparing several company executives for trial testimony, and was lead drafter on significant briefs.

In re Aggrenox Antitrust Litigation – Defense of pharmaceutical company Boehringer Ingelheim against allegations of an anticompetitive "reverse payment" patent settlement relating to the blockbuster drug Aggrenox®. Kathryn helped manage the case through the Multi-District Litigation (MDL) process, oversaw discovery including the production of millions of documents, the use of contract reviewers, and negotiations with opposition counsel, and Kathryn drafted and presented oral argument before the Second Circuit, which affirmed the challenged class action settlement.

Advise clients on distribution pricing issues under the Robinson-Patman Act.

Doryx – Defended Allegan/Warner Chilcott against competitor Mylan's claims challenging Warner Chilcott's transition to new versions of its Doryx® acne treatment. Kathryn was a member of the team that won dismissal of all of the plaintiff's claims on summary judgment—the first ever full evidentiary record victory for a defendant in a so-called pharmaceutical "product hopping" litigation.

Former employee of a leading commodities broker – Represented client in an alleged US$600 million fraud involving the valuation of natural gas options positions by a major Canadian bank.

Pilot Travel Centers LLC, Pilot Flying J – Defense of largest over-the-road diesel provider in the US, as national in more than 20 putative class actions.